ANAB - AnaptysBio Inc

62.01
2.310   3.725%

Share volume: 527,805
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$59.70
2.31
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
60%
Profitability 46%
Dept financing 41%
Liquidity 50%
Performance 80%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
11.91%
1 Month
12.24%
3 Months
35.45%
6 Months
167.28%
1 Year
253.53%
2 Year
165.57%
Key data
Stock price
$62.01
P/E Ratio 
N/A
DAY RANGE
$59.55 - $62.30
EPS 
-$0.46
52 WEEK RANGE
$15.32 - $63.47
52 WEEK CHANGE
$250.14
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
28.748 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$585,593
AVERAGE 30 VOLUME 
$488,569
Company detail
CEO: Daniel R. Faga
Region: US
Website: anaptysbio.com
Employees: 100
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AnaptysBio, Inc. engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.

Recent news